Case: 1:17-md-02804-DAP Doc #: 1896-23 Filed: 07/19/19 1 of 9. PageID #: 75674

Exhibit 20

	Page 1
1	UNITED STATES DISTRICT COURT
2	NORTHERN DISTRICT OF OHIO
3	EASTERN DIVISION
3 4	EASIERN DIVISION
5	
	~~~~~~~~~~~~~~~~~
6	THE RESIDENCE PROGRAMMENT AND A SOLIT
7	IN RE: NATIONAL PRESCRIPTION MDL No. 2804
-	OPIATE LITIGATION
8	Case No.
	17-md-2804
9	_
	Judge Dan Aaron
10	Polster
11	This document relates to:
12	The County of Summit, Ohio, et al. v. Purdue
	Pharma L.P., et al.
13	
	Case No. 18-OP-45090 (N.D. Ohio)
14	
15	
	~~~~~~~~~~~~~~~~
16	
	Videotaped Deposition of
17	STEVE PERCH
18	October 18, 2018
	9:00 a.m.
19	
20	
	Taken at:
21	
	Brennan Manna & Diamond
22	75 East Market Street
	Akron, Ohio
23	
24	
25	Stephen J. DeBacco, RPR

```
Page 2
    APPEARANCES:
1
2
3
           On behalf of the City of Akron, Summit
           County, and the Witness:
4
                 Motley Rice LLC, by
5
                 ANNE MCGINNESS KEARSE, ESQ.
                 KRISTEN M. HERMIZ, ESQ.
                 28 Bridgeside Boulevard
6
                 Mt. Pleasant, South Carolina 29464
7
                 (843) 216-9140
                 akearse@motleyrice.com
                 (843) 216-9390
8
                 khermiz@motleyrice.com
9
           On behalf of McKesson Corporation, via
10
           teleconference:
11
                 Covington & Burling LLP, by
                 PATRICK R. CAREY, ESQ.
12
                 One Front Street
13
                 San Francisco, California 94111-5356
                 (415) 591-7093
14
                 pcarey@cov.com
15
           On behalf of Walmart, Inc.:
16
                 Jones Day, by
17
                 EDWARD M. CARTER, ESQ.
                 BRANDY H. RANJAN, ESQ.
                 325 John H. McConnell Boulevard
18
                 Suite 600
19
                 Columbus, Ohio 43216-5017
                 (614) 281-3906
20
                 emcarter@jonesday.com
                 (614) 469-3939
21
                 branjan@jonesday.com
22
                         ~ ~ ~ ~ ~
23
24
25
```

```
Page 3
    APPEARANCES, Continued:
1
           On behalf of Cardinal Health, Inc.:
3
                 Williams & Connolly LLP, by
                 MIRANDA PETERSEN, ESQ.
4
                 725 12th Street Northwest
                 Washington, D.C. 20005
5
                 (202) 434-5686
                 mpetersen@wc.com
6
7
           On behalf of Prescription Supply, Inc.:
8
                 Pelini, Campbell & Williams, by
9
                 GIANNA M. CALZOLA-HELMICK, ESQ.
                 Bretton Commons, Suite 400
                 8040 Cleveland Avenue Northwest
10
                 North Canton, Ohio 44720
                 (330) 305-6400
11
                 qiannac@pelini-law.com
12
1.3
           On behalf of Endo Pharmaceuticals, Inc.,
           Endo Health Solutions, Inc., Par
14
           Pharmaceuticals, Inc. and Par
           Pharmaceutical Companies, Inc.:
15
                 Arnold & Porter Kaye Scholer LLP, by
16
                 ANGEL TANG NAKAMURA, ESQ.
                 777 South Figueroa Street
                 44th Floor
17
                 Los Angeles, California 90017-5844
18
                 (213) 243-4094
                 angel.nakamura@arnoldporter.com
19
20
21
22
23
24
25
```

```
Page 4
    APPEARANCES, Continued:
1
           On behalf of Johnson & Johnson and
           Janssen Pharmaceuticals, Inc.:
3
4
                 Tucker Ellis LLP, by
                 JUSTIN E. RICE, ESQ.
                 950 Main Avenue North, Suite 1100
5
                 Cleveland, Ohio 44113
                 (216) 696-3670
6
                 justin.rice@tuckerellis.com
7
           On behalf of AmerisourceBergen:
8
                 Jackson Kelly PLLC, by
9
                 A.L. EMCH, ESQ.
                 1600 Laidley Tower
10
                 P.O. Box 553
                 Charleston, West Virginia 25332
11
                 (304) 340-1172
12
                 aemch@jacksonkelly.com
13
                 -and-
14
                 Jackson Kelly PLLC, by
                 SANDRA K. ZERRUSEN, ESQ.
15
                 50 South Main Street, Suite 201
                 Akron, Ohio 44308
16
                 (330) 252-9060
                 skzerrusen@jacksonkelly.com
17
18
           On behalf of Cephalon, Inc.; Teva
           Pharmaceuticals USA, Inc.; Actavis, LLC;
           Actavis Pharma, Inc. F/k/a Watson Pharma,
19
           Inc.; and Watson Laboratories, Inc., via
20
           teleconference:
                 Morgan, Lewis & Bockius LLP, by
21
                 PAMELA HOLLY, ESQ.
22
                 101 Park Avenue
                 New York, New York 10178-0060
                 (212) 309-6864
23
                 pamela.holly@morganlewis.com
24
25
```

```
Page 5
1
    APPEARANCES, Continued:
           On behalf of Purdue Pharma L.P., Purdue
2
           Pharma, Inc., and The Purdue Frederick
           Company:
3
                 Dechert LLP, by
4
                 MARK S. CHEFFO, ESQ.
5
                 3 Bryant Park
                 1095 Avenue of the Americas
6
                 New York, New York 10036-6797
                 (212) 698-3814
7
                 markcheffo@dechert.com
                 -and-
8
                 Dechert LLP
9
                 SARA B. ROITMAN, ESQ.
                 35 West Wacker Drive, Suite 3400
10
                 Chicago, Illinois 60601-1634
                 (312) 646-5800
11
                 sara.roitman@dechert.com
12
13
           On behalf of Allergan Finance, LLC, via
           Teleconference:
14
                 Kirkland & Ellis LLP, by
15
                 PAUL J. WEEKS, ESQ.
                 655 Fifteenth Street, Northwest
                 Washington, D.C. 20005-5793
16
                 (202) 879-5148
17
                 paul.weeks@kirkland.com
18
           On behalf of HBC Service Company, Inc.,
           via teleconference:
19
20
                 Marcus & Shapira LLP, by
                 JAMES F. ROSENBERG, ESQ.
                 One Oxford Centre, 35th Floor
21
                 Pittsburgh, Pennsylvania 15219
                 (412) 338-4683
22
                 rosenberg@marcus-shapira.com
23
     ALSO PRESENT:
24
                 Nick Cummings, Motley Rice
25
                 Jim Torok, Legal Videographer
```

	Page 6
1	TRANSCRIPT INDEX
2	
3	APPEARANCES
4	
5	INDEX OF EXHIBITS 7
6	
7	EXAMINATION OF STEVE PERCH
8	By Mr. Cheffo
9	By Mr. Emch
10	By Mr. Carter 218
11	By Ms. Kearse 228
12	By Mr. Carter 230
13	
14	REPORTER'S CERTIFICATE 232
15	
16	EXHIBIT CUSTODY
17	EXHIBITS RETAINED BY THE COURT REPORTER
18	
19	
2 0	
21	
22	
23	
24	
25	

Page 185 flip to the next page, she's referring to that 1 bar chart that we talked about a little bit 2. earlier? 3 Α. Correct. 4 And again, I'm not going to ask 5 lots of specific questions, but would you agree 6 7 with me that the carfentanil deaths were largely in one time -- kind of point in time in 8 9 2016 where you saw very significant deaths 10 associated to carfentanil? 11 Α. No. 12 What -- did it occur after 2016? 0. 1.3 Α. I will agree with you that it started in the 4th of July weekend of 2016 and 14 just ballooned for the rest of 2016. It didn't 15 get any better. It got worse. And then 2017 16 17 was just as bad. 18 0. Okay. So that year and a half was 19 20 carfentanil. It was, you know, basically the carfentanil epidemic. 21 22 Now, prior to that, when I first started the coroner's office, as I mentioned 23 before, I would see trends. You know, 24 initially in the early 2000s, hydrocodone, 25

Veritext Legal Solutions
www.veritext.com
888-391-3376

Page 186

oxycodone, and that lasted for years. I mean,you see peaks and valleys and spikes.

But typically what all I saw the first 10 years at the coroner's office were prescription meds. Very low levels of illicit drugs in terms of lethal nature. Most of our deaths -- and I don't have the statistics. This is just the perception I had.

O. Uh-huh.

2.2

A. The first 10 years I'm there.

Then, the last 10 years, I saw some fluctuations. You know, the prescription -- as I mentioned, we had pain management centers back then, quite a few of them. As a matter of fact, my last few years at City Hospital I created a special drug test aimed at pain management centers where I incorporated the things that they wanted to see, which is the opiates: oxycodone, hydrocodone, Fentanyl, methadone, et cetera. And we called it the pain management panel.

We originally created it for St. Thomas Hospital. And after several weeks, we were getting calls from Cleveland Clinic,

Aultman Hospital. Cleveland Clinic would have